Jazz Pharmaceuticals JAZZ Additional expected tax expense if foreign earnings repatriated
Additional expected tax expense if foreign earnings repatriated at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept jazz:AdditionalExpectedTaxExpenseIfForeignEarningsRepatriatedInTheFuture.
The official record: Jazz Pharmaceuticals’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's additional expected tax expense if foreign earnings repatriated.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's additional expected tax expense if foreign earnings repatriated?
- Jazz Pharmaceuticals (JAZZ) reported additional expected tax expense if foreign earnings repatriated of $14M in Q4 2025.
- How has Jazz Pharmaceuticals's additional expected tax expense if foreign earnings repatriated changed year-over-year?
- Jazz Pharmaceuticals's additional expected tax expense if foreign earnings repatriated decreased by 30.9% year-over-year, from $20.25M to $14M.
- What is the long-term trend for Jazz Pharmaceuticals's additional expected tax expense if foreign earnings repatriated?
- Over 4 years (2021 to 2025), Jazz Pharmaceuticals's additional expected tax expense if foreign earnings repatriated has grown at a -16.1% compound annual growth rate (CAGR), from $113M to $56M.
- What does additional expected tax expense if foreign earnings repatriated mean?
- The estimated tax cost of bringing foreign profits back to the home country.
- How do you interpret additional expected tax expense if foreign earnings repatriated?
- Higher amounts indicate significant trapped cash in foreign jurisdictions with high repatriation tax costs.
- How does additional expected tax expense if foreign earnings repatriated compare across companies?
- Commonly disclosed by multinational firms to assess capital allocation flexibility.